Regardless of OS or DSS, the prognosis of patients with high MCTS1 expression was notably more unfavorable in several subgroups, including T1 and T2, N2 and N3, M0, stage II and III, age >60 years, estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, HER2-positive, Luminal B, and infiltrating ductal carcinoma (IDC) subgroups (all p < 0.05) (Figure 9). This evidence concerns the gene MCTS1 and invasive ductal breast carcinoma.